Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CM-101 · 1 trial · 3 indications
Incidence and characteristics of adverse events (AEs) occurring following single subcutaneous doses of CM-101
Maximum CM-101 plasma concentration (Cmax)
Time to Cmax (tmax)
Area under the curve (AUC) to the final concentration ≥ limit of quantitation (LOQ), AUC(0-t) and to infinity AUCinf
Terminal elimination rate constant (λz)
Terminal elimination half-life (T½)
| Arm | Type | Description |
|---|---|---|
| Anti-human CCL24 monoclonal antibody (CM-101) | EXPERIMENTAL | Single 5 mg/kg of CM-101, Subcutaneous administration |
| Placebo | PLACEBO_COMPARATOR | Placebo : Subcutaneous administration |
| Name | Type | Description |
|---|---|---|
| CM-101 | DRUG | Anti-human CCL24 monoclonal antibody (CM-101) |
| Placebo | DRUG | Placebo Comparator |
Inclusion Criteria: 1. Subjects must provide written informed consent prior to participating in the study. 2. Considered healthy by the Investigator as defined by no clinically relevant abnormalities identified by a detailed medical history, full physical examination, 12-lead ECG, and clinical labo...
CM-101 is an investigational small molecule being developed for Nonalcoholic Steatohepatitis (NASH). It is also being studied for medical conditions involving inflammatory and fibrotic mechanisms, including Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc).
CM-101 is being developed by Chemomab Therapeutics Ltd., a biopharmaceutical company. The company's stock is traded under the ticker symbol CMMB.
CM-101 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 trial has been completed, and the drug remains in early-stage clinical testing.
CM-101 has one completed Phase 1 clinical trial, identified as NCT06037577. This trial evaluated subcutaneous doses of CM-101 in healthy male subjects for conditions involving inflammatory and fibrotic mechanisms, including NASH, PSC, and SSc.
CM-101 is the sole name provided for this investigational drug. No alternative names have been reported for this asset.